Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Antihyperglycemics, DPP-4 Inhibitors, DPP-4 Combination (Metformin, Thiazolidinedione)
Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Antihyperglycemics, DPP-4 Inhibitors, DPP-4 Combination (Metformin, Thiazolidinedione).** Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: Pharmacy | Community Provider Portal | Kaiser Permanente

Medications:

• ALOGLIPTIN-PIOGLITAZONE • OSENI • ALOGLIPTIN BENZOATE • ALOGLIPTIN-METFORMIN • JANUMET, JANUMET XR	• JANUVIA • KAZANO • KOMBIGLYZE XR • NESINA • ONGLYZA

1 – Patient Information

Patient Name: ______________________________ Kaiser Medical ID#: _________________ Date of Birth: _____________

2 – Prescriber Information

Prescriber Name: ______________________________ Specialty: ____________________________ NPI: _________________

Prescriber Address: ____

Prescriber Phone #: __________________________Prescriber Fax #: ___________________________

Do you have an approved provider referral number from Kaiser Permanente?

□ Yes – please provide your provider referral number here: ________________

3 – Pharmacy Information

Pharmacy Name: ________________________________ Pharmacy NPI: ____

Pharmacy Phone #_______________________________ Pharmacy Fax #: ____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: ____

Sig: ____

Drug 2: Name/Strength/Formulation: ____

Sig: ____

5– Diagnosis/Clinical Criteria

1. Is this request for initial or continuing therapy?
   □ Initial therapy □ Continuing therapy, State date: _________________________

2. Indicate the patient's diagnosis for the requested medication: ___________________________________

Clinical Criteria:

1. Does the member have a diagnosis of type 2 diabetes mellitus?
   □ No □ Yes

2. Is the member ≥18 years old?
   □ No □ Yes

3. Is the HbA1c within 2% above goal (as per ADA guidelines) within 90 days of the PA request *(Note: if A1c is >2% above goal, insulin therapy is recommended)*?
   □ No □ Yes

4. Is the member on another DPP-4 inhibitor, or any agent within the GLP-1 agonist drug class?
   □ No □ Yes

5. Has the patient had an adequate trial (90 days) of ALL of the following medications for diabetes, unless allergy or intolerance*?
   a. Metformin
   b. Sulfonylurea
   c. Pioglitazone (if BMI <35)
   d. Jardiance
   e. Tradjenta
   f. Victoza[*PA]
   □ No □ Yes

[*PA] *This medication is also subject to PA review*

For continuation of therapy, please respond to <u>additional questions</u> below.

1. Is there documented A1C lowering of 0.5% from initial or A1C now at goal?
   □ No □ Yes

NOTES:
* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment and do not require medication discontinuation

6 – Prescriber Sign-Off

Additional Information –

1. **Please submit chart notes/medical records for the patient that are applicable to this request.**
2. **If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:**

____

____

____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	Date:

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility